Investigating cardiovascular risk reduction – the Rosuvastatin GALAXY Programme^™

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.5, 2004-05, pp. : 1187-1200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular risk reduction targets in diabetes

Inpharma, Vol. 1, Iss. 1430, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Cardiovascular Risk Reduction in the Extreme Elderly

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 1, 2013-03 ,pp. : 62-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hyperhomocysteinemia and Cardiovascular Risk: Effect of Vitamin Supplementation in Risk Reduction

Current Clinical Pharmacology, Vol. 5, Iss. 1, 2010-01 ,pp. : 30-36

Bentham Science Publishers

Access to resources Recommend Favorite

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

By Barrios Vivencio Escobar Carlos

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 9, 2010-06 ,pp. : 1549-1558

Informa Healthcare

Access to resources Recommend Favorite

Novel Concepts of Statin Therapy for Cardiovascular Risk Reduction in Hypertension

Current Pharmaceutical Design, Vol. 12, Iss. 13, 2006-05 ,pp. : 1593-1609

Bentham Science Publishers

Access to resources Recommend Favorite